

REMARKS/ARGUMENTS

Claims 1-20 are active. Claim 1 has been revised to refer to further characterize mature prolactin as having cysteine residues at positions 4 and 11, alanine at position 22, and glycine at position 129. Support for these terms is found on page 5, lines 18 and 26. The term "binding site 2" is described *inter alia* on page 2, lines 22 *ff.* of the specification and has previously been characterized by Goffin, et al., Endocr. Rev. 17: 385-410. Claim 10 has been revised in light of page 8, lines 18-21. New claim 13 finds similar support in original claim 1 and on page 5 of the specification. Claims 14-15 find support on page 5, lines 17-20; claims 16-17 at page 6, lines 3-6; and claims 18 and 20 in the section bridging pages 4-5 and claim 19 on page 6, lines 7-8 and original claim 12. Accordingly, the Applicants do not believe that any new matter has been added. Favorable consideration of this amendment and allowance of this application are respectfully requested.

Objection--Title

The Title was objected to as not being adequately descriptive. This issue is now moot.

Objection--Claims

Claims 6-9 and 12 were objected to as being in improper multiple dependent form. This objection is moot in view of the amendments above.

Rejection-- 35 U.S.C. §112, second paragraph

Claims 1-5 and 12 were rejected under 35 U.S.C. 112, second paragraph, as being indefinite. The Applicants believe that this rejection is now moot.

Conclusion

In view of the amendments and remarks above, the Applicants respectfully submit that this application is now in condition for allowance. An early notice to that effect is earnestly solicited.

Respectfully submitted,


OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.

Norman F. Oblon

Customer Number

22850

Tel: (703) 413-2220
Fax: (703) 413-2220
(OSMMN 08.03)
NFO/TMC:sih


Thomas M. Cunningham, Ph.D.
Registration No. 45,394